Not available
Quote | Exact Sciences Corporation (NASDAQ:EXAS)
Last: | $64.08 |
---|---|
Change Percent: | 2.68% |
Open: | $62.6 |
Close: | $62.41 |
High: | $65 |
Low: | $62.415 |
Volume: | 958,425 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Exact Sciences Corporation (NASDAQ:EXAS)
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
2024-04-19 03:54:17 ET Summary ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, making up around 20% of the assets. ARK Invest ...
Message Board Posts | Exact Sciences Corporation (NASDAQ:EXAS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $EXAS News Article - Exact Sciences schedules first quarter 2023 earnings call | whytestocks | investorshangout | 04/10/2023 12:20:49 PM |
znewcar1: $EXAS 24% v10,8M c58.82 f177,684M H60.93 gapNgo to HOD | znewcar1 | investorshangout | 01/09/2023 11:12:13 PM |
whytestocks: $EXAS News Article - Medicare and Insurance Policy Updates in 2023 Will Improve Cancer | whytestocks | investorshangout | 12/20/2022 3:30:56 PM |
$EXAS up big time in the pre-market. I've | OldAIMGuy | investorshub | 12/16/2022 1:37:32 PM |
GH(-34%/AH)reports_results_of Shield ctDNA(liquid biopsy)diagnostic_for co | DewDiligence | investorshub | 12/16/2022 12:06:42 AM |
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-04-15 11:30:02 ET William Blair analyst issues OUTPERFORM recommendation for EXAS on April 15, 2024 10:21AM ET. The previous analyst recommendation was Outperform. EXAS was trading at $68.965 at issue of the analyst recommendation. The overall analyst consensus : BU...
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. ...
First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test 1 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic t...